https://www.thebodypro.com/category/genvoya-pro

Cobicistat/Emtricitabine/Elvitegravir/Tenofovir Alafenamide (Genvoya, E/C/F/TAF)

The Latest

Contraception pills on blue background
News

This Week in HIV Research: Cracking the Contraception Conundrum

July 11, 2019: Seroconversion while on long-acting contraceptives; cardiovascular risk in people with HIV; suboptimal testing in high-prevalence U.S. areas; E/C/F/TAF may be suitable for PEP.

Putting test tubes into the holder
News

This Week in HIV Research: I Screen, You Screen, We All Screen for HPV-Related Cancers

May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.

illustration of person on cliff with arms raised as sun rises/sets
News

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors Img
Neurocognitive

Large French Study Examines Neuropsychiatric Side Effects With Integrase Inhibitors

This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects Img
Conference Coverage

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

Promo Image
News

This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

Switching to Genoya Plus Prezista Maintains Viral Suppression, Improves Renal Markers Img
Kidney

Switching to Genoya Plus Prezista Maintains Viral Suppression, Improves Renal Markers

Switching from a suppressive five-drug regimen to Genvoya and Prezista proved virologically noninferior to maintaining the initial regimen at 24 weeks and virologically superior at 48 weeks.

Integrase Inhibitors and Their Effectiveness and Safety in Women Img
Women

Integrase Inhibitors and Their Effectiveness and Safety in Women

Results from two studies show that not only do integrase inhibitor-based regimens work well in women, but that they better tolerated than a regimen based on the protease inhibitor atazanavir.

FDA Approved Changes to the Genvoya Label Img
News

FDA Approved Changes to the Genvoya Label

FDA recently approved changes to the Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) fixed-dose combination tablet product labeling.

Genvoya Approved in Canada: What You Need to Know Img
News

Genvoya Approved in Canada: What You Need to Know

Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) is a complete treatment in one pill that comes in the form of green capsule-shaped tablets. The dose of Genvoya used by adults with HIV is one tablet once daily with food.